Leader in Biomolecular Solutions for Life Science

www.abclonal.com

Human CD20 Monoclonal Antibody

Catalog No.: YR0130

Basic Information

Molecular Weight
150 kDa

Endotoxin
<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay

Sterility
0.2 μm filtration

Aggregation
<5% Determined by SECP

Purity
>95% Determined by SDS-PAGE

Background

Obinutuzumab is an antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil.In contrast to rituximab, which is a classic type I CD20 antibody, obinutuzumab binds to type II CD20 antibodies. This allows obinutuzumab to have a much higher induction of antibody-dependant cytotoxicity and a higher direct cytotoxic effect than the classic CD20 antibodies.

Reported Applications

ELISA,neutralization,functional assays such as bioanalytical PK and ADA assays,and those assays for studying biological pathways

Immunogen Information

Clone
Obinutuzumab Biosimilar

Isotype
Human IgG1 kappa

Immunogen
Human CD20

RecommendedIsotype Control(s)
In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody

Recommended Dilution Buffer
1×PBS pH 6.0

Contact

400-999-6126

cn.market@abclonal.com.cn

www.abclonal.com.cn

Product Information

Production
Purified from cell culture supernatant in an animal-free facility

Purification
Protein A or G purification

Storage
Store at -20℃